100 related articles for article (PubMed ID: 12144949)
1. Effects of cholecystokinin octapeptide on the exocrine pancreas in a new rat model of type 2 diabetes.
Kuntz E; Pinget M; Damgé C
Eur J Pharmacol; 2002 Jul; 448(2-3):253-61. PubMed ID: 12144949
[TBL] [Abstract][Full Text] [Related]
2. Modulation of exocrine pancreatic secretion by leptin through CCK(1)-receptors and afferent vagal fibres in the rat.
Guilmeau S; Nagain-Domaine C; Buyse M; Tsocas A; Rozé C; Bado A
Eur J Pharmacol; 2002 Jun; 447(1):99-107. PubMed ID: 12106809
[TBL] [Abstract][Full Text] [Related]
3. Stimulation of growth of azaserine-induced putative preneoplastic lesions in rat pancreas is mediated specifically by way of cholecystokinin-A receptors.
Povoski SP; Zhou W; Longnecker DS; Roebuck BD; Bell RH
Cancer Res; 1993 Sep; 53(17):3925-9. PubMed ID: 8358719
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent pancreatotrophic effect of cholecystokinin-octapeptide in the rat: the influence of starvation.
Nagy I; Lászik Z; Mohácsi G
Pharmacol Res; 1998 Apr; 37(4):309-19. PubMed ID: 9634648
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of exocrine pancreatic insufficiency in streptozotocin-induced type 1 diabetes mellitus.
Patel R; Shervington A; Pariente JA; Martinez-Burgos MA; Salido GM; Adeghate E; Singh J
Ann N Y Acad Sci; 2006 Nov; 1084():71-88. PubMed ID: 17151294
[TBL] [Abstract][Full Text] [Related]
6. Effects of cholecystokinin octapeptide on a pancreatic acinar carcinoma in the rat.
Hajri A; Damgé C
Pharm Res; 1998 Nov; 15(11):1767-74. PubMed ID: 9834001
[TBL] [Abstract][Full Text] [Related]
7. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats.
Kuntz E; Pinget M; Damgé P
JOP; 2004 Nov; 5(6):464-75. PubMed ID: 15536283
[TBL] [Abstract][Full Text] [Related]
10. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells.
Dawra R; Saluja A; Lerch MM; Saluja M; Logsdon C; Steer M
Biochem Biophys Res Commun; 1993 Jun; 193(3):814-20. PubMed ID: 8323557
[TBL] [Abstract][Full Text] [Related]
11. Are C-terminal octapeptide of cholecystokinin and [Leu11]gastrin-(5-17) different in stimulating acid secretion in isolated rabbit gastric glands?
Oiry C; Galleyrand JC; Lima-Leite AC; Fulcrand P; Martinez J
Eur J Pharmacol; 1995 Dec; 294(2-3):511-9. PubMed ID: 8750713
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin receptor characterization and cholecystokinin-A receptor messenger RNA expression in transgenic mouse pancreatic carcinomas and dysplastic pancreas.
Povoski SP; Zhou W; Longnecker DS; Bell RH
Oncol Res; 1994; 6(9):411-7. PubMed ID: 7703527
[TBL] [Abstract][Full Text] [Related]
13. Visualization and characterization of CCK receptors in exocrine pancreas of rat with storage phosphor autoradiography.
Tang C; Biemond I; Lamers CB
Pancreas; 1996 Oct; 13(3):311-5. PubMed ID: 8884854
[TBL] [Abstract][Full Text] [Related]
14. Occupation of low-affinity cholecystokinin (CCK) receptors by CCK activates signal transduction and stimulates amylase secretion in pancreatic acinar cells.
Vinayek R; Patto RJ; Menozzi D; Gregory J; Mrozinski JE; Jensen RT; Gardner JD
Biochim Biophys Acta; 1993 Mar; 1176(1-2):183-91. PubMed ID: 7680902
[TBL] [Abstract][Full Text] [Related]
15. Effects of the CCK receptor antagonist L364,718 on pancreatic growth in adult and developing animals.
Zucker KA; Adrian TE; Bilchik AJ; Modlin IM
Am J Physiol; 1989 Oct; 257(4 Pt 1):G511-6. PubMed ID: 2478030
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function.
Tachibana I; Kanagawa K; Yamamoto Y; Otsuki M
J Pharmacol Exp Ther; 1996 Dec; 279(3):1404-12. PubMed ID: 8968365
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini.
Talkad VD; Patto RJ; Metz DC; Turner RJ; Fortune KP; Bhat ST; Gardner JD
Biochim Biophys Acta; 1994 Oct; 1224(1):103-16. PubMed ID: 7524683
[TBL] [Abstract][Full Text] [Related]
19. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
Chang RS; Lotti VJ; Chen TB
Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
[TBL] [Abstract][Full Text] [Related]
20. Little or no expression of the cholecystokinin-A receptor gene in the pancreas of diabetic rats (Otsuka Long-Evans Tokushima Fatty = OLETF rats).
Funakoshi A; Miyasaka K; Jimi A; Kawanai T; Takata Y; Kono A
Biochem Biophys Res Commun; 1994 Mar; 199(2):482-8. PubMed ID: 8135789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
